Vertex Pharmaceuticals stock holds at EUR 464.53 as UBS lifts target

Vertex Pharmaceuticals (ISIN US92532F1003) was trading at EUR 464.53 at Lang & Schwarz on September 30, 2026, at 9:46 a.m. CEST, up 0.02 percent versus the prior close of EUR 464.45. Investing.com reported on September 28, 2026, that UBS raised its Vertex target from USD 585.00 to USD 615.00 while maintaining a Buy rating.

Kidney data drive target revisions

The UBS case centers on inaxaplin, Vertex's oral treatment for APOL1-mediated kidney disease. The firm cited Phase III data expected in early 2027 and said the stock could move 10 percent to 15 percent if the interim results are positive.

A Finanznachrichten page carrying the company's September 22, 2026 release said inaxaplin reduced UACR by 42.70 percent at Week 13 in the modest-proteinuria cohort and by 17.30 percent in the type 2 diabetes cohort. Vertex also said enrollment in the Phase 2/3 AMPLITUDE trial was complete, with interim analysis targeted for early 2027.

Q2 revenue beats expectations

Vertex's Q2 2026 revenue reached USD 3.33 billion, up 12.50 percent year over year, while adjusted EPS was USD 4.73. Investing.com reported that revenue exceeded the USD 3.22 billion consensus and adjusted EPS topped the USD 4.72 estimate.

The contrast matters for valuation: operating performance is expanding, while the pipeline now supplies a second growth narrative beyond cystic fibrosis. Investing.com lists Vertex's USD 133.68 billion market capitalization and a USD 385.86 to USD 560.25 52-week range as of September 29, 2026.

Stock stays below yearly high

Investing.com identifies Vertex as a NASDAQ-listed company with the ticker VRTX and the ISIN US92532F1003. The next earnings report is scheduled for November 9, 2026, according to the same company profile.

At Lang & Schwarz, Vertex Pharmaceuticals was trading at EUR 464.53 on September 30, 2026, at 9:46 a.m. CEST, plus 0.02 percent against the prior close of EUR 464.45.

More news and analyses on Vertex Pharmaceuticals stock